Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
BackgroundImmunotherapy, particularly the utilization of immune checkpoint inhibitors (ICIs), assumes a pivotal role in the comprehensive management of advanced lung cancer. There has been substantial deliberation regarding the appropriateness of extending ICIs treatment beyond the point of disease...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266992/full |
| _version_ | 1797682379806998528 |
|---|---|
| author | Chao Chen Xi Xiong Ying Cheng Haiyun Gen Wenqiang Zhu Fei Zhang Chuandong Zhu Siqi Han Xiufeng Liu |
| author_facet | Chao Chen Xi Xiong Ying Cheng Haiyun Gen Wenqiang Zhu Fei Zhang Chuandong Zhu Siqi Han Xiufeng Liu |
| author_sort | Chao Chen |
| collection | DOAJ |
| description | BackgroundImmunotherapy, particularly the utilization of immune checkpoint inhibitors (ICIs), assumes a pivotal role in the comprehensive management of advanced lung cancer. There has been substantial deliberation regarding the appropriateness of extending ICIs treatment beyond the point of disease progression. This study delves into the potential benefits of sustained utilization of ICIs subsequent to disease progression in patients.MethodsA retrospective analysis was conducted on a cohort of 248 patients diagnosed with advanced lung cancer who received treatment with ICIs. The study population comprised 99 patients in the treatment beyond progression (TBP) group and 42 patients in the non-treatment beyond progression (NTBP) group. Parameters including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were assessed. The Cox proportional hazard regression model was employed to analyze prognostic factors related to immunotherapy.ResultsPatients undergoing primary treatment with PD-1/PD-L1 inhibitors exhibited a median progression-free survival (mPFS) of 5.3 months. In the context of disease progression, a comparison between the TBP and NTBP groups was performed with respect to mPFS. The results demonstrated that the TBP group manifested an mPFS of 8.6 months, contrasting with the NTBP group’s mPFS of 4.0 months (p=0.028). The mean overall survival (mOS) in the TBP group exhibited a statistically significant increase in comparison to the NTBP group (14.1 months vs. 6.0 months, p=0.028). Evaluation of the objective response rate (ORR) between the TBP and NTBP groups revealed a substantial distinction. The TBP group displayed an ORR of 12.1%, while the NTBP group exhibited a lower ORR of 2.4%. The statistical analysis yielded a p-value of 0.068, signifying a notable trend towards significance. The disease control rate (DCR) was also assessed and exhibited a noteworthy variance between the two groups, with a higher DCR of 92.9% in contrast to 71.4% in the control group (p = 0.001).ConclusionSubsequent to ICIs treatment, a subset of patients may derive continued benefits from anticancer therapy, notwithstanding the progression of their advanced lung cancer. |
| first_indexed | 2024-03-11T23:59:48Z |
| format | Article |
| id | doaj.art-2086c1cdd3ee44ed9a0ab6b50854c1dd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T23:59:48Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2086c1cdd3ee44ed9a0ab6b50854c1dd2023-09-18T05:03:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12669921266992Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progressionChao Chen0Xi Xiong1Ying Cheng2Haiyun Gen3Wenqiang Zhu4Fei Zhang5Chuandong Zhu6Siqi Han7Xiufeng Liu8Department of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Hepatology, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Surgical Oncology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Clinical Laboratory, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaBackgroundImmunotherapy, particularly the utilization of immune checkpoint inhibitors (ICIs), assumes a pivotal role in the comprehensive management of advanced lung cancer. There has been substantial deliberation regarding the appropriateness of extending ICIs treatment beyond the point of disease progression. This study delves into the potential benefits of sustained utilization of ICIs subsequent to disease progression in patients.MethodsA retrospective analysis was conducted on a cohort of 248 patients diagnosed with advanced lung cancer who received treatment with ICIs. The study population comprised 99 patients in the treatment beyond progression (TBP) group and 42 patients in the non-treatment beyond progression (NTBP) group. Parameters including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were assessed. The Cox proportional hazard regression model was employed to analyze prognostic factors related to immunotherapy.ResultsPatients undergoing primary treatment with PD-1/PD-L1 inhibitors exhibited a median progression-free survival (mPFS) of 5.3 months. In the context of disease progression, a comparison between the TBP and NTBP groups was performed with respect to mPFS. The results demonstrated that the TBP group manifested an mPFS of 8.6 months, contrasting with the NTBP group’s mPFS of 4.0 months (p=0.028). The mean overall survival (mOS) in the TBP group exhibited a statistically significant increase in comparison to the NTBP group (14.1 months vs. 6.0 months, p=0.028). Evaluation of the objective response rate (ORR) between the TBP and NTBP groups revealed a substantial distinction. The TBP group displayed an ORR of 12.1%, while the NTBP group exhibited a lower ORR of 2.4%. The statistical analysis yielded a p-value of 0.068, signifying a notable trend towards significance. The disease control rate (DCR) was also assessed and exhibited a noteworthy variance between the two groups, with a higher DCR of 92.9% in contrast to 71.4% in the control group (p = 0.001).ConclusionSubsequent to ICIs treatment, a subset of patients may derive continued benefits from anticancer therapy, notwithstanding the progression of their advanced lung cancer.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266992/fulladvanced lung cancerPD-1treatment beyond progressionimmunotherapyretrospective study |
| spellingShingle | Chao Chen Xi Xiong Ying Cheng Haiyun Gen Wenqiang Zhu Fei Zhang Chuandong Zhu Siqi Han Xiufeng Liu Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression Frontiers in Immunology advanced lung cancer PD-1 treatment beyond progression immunotherapy retrospective study |
| title | Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| title_full | Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| title_fullStr | Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| title_full_unstemmed | Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| title_short | Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| title_sort | expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression |
| topic | advanced lung cancer PD-1 treatment beyond progression immunotherapy retrospective study |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266992/full |
| work_keys_str_mv | AT chaochen expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT xixiong expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT yingcheng expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT haiyungen expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT wenqiangzhu expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT feizhang expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT chuandongzhu expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT siqihan expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression AT xiufengliu expandingtheapplicationsofimmunecheckpointinhibitorsinadvancedlungcancerbeyonddiseaseprogression |